These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11404035)

  • 1. Stabilization of minodronic acid in aqueous solution for parenteral formulation.
    Nakamura K; Tanaka T; Saito K; Yokohama S; Sonobe T
    Int J Pharm; 2001 Jul; 222(1):91-9. PubMed ID: 11404035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failure of stability prediction for minodronic acid injectable by accelerated stability testing.
    Nakamura K; Yokohama S; Sonobe T
    Int J Pharm; 2002 Jul; 241(1):65-71. PubMed ID: 12086722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new stressed test to predict the foreign matter formation of minodronic acid in solution.
    Nakamura K; Yokohama S; Katsuma M; Sawada T; Sonobe T
    Int J Pharm; 2003 Jan; 251(1-2):99-106. PubMed ID: 12527179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer.
    Avanti C; Amorij JP; Setyaningsih D; Hawe A; Jiskoot W; Visser J; Kedrov A; Driessen AJ; Hinrichs WL; Frijlink HW
    AAPS J; 2011 Jun; 13(2):284-90. PubMed ID: 21448747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parenteral formulation of Flavopiridol (NSC-649890).
    Dannenfelser RM; Surakitbanharn Y; Tabibi SE; Yalkowsky SH
    PDA J Pharm Sci Technol; 1996; 50(6):356-9. PubMed ID: 9038080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum elution and precipitation in glass vials: effect of pH and buffer species.
    Ogawa T; Miyajima M; Wakiyama N; Terada K
    Drug Dev Ind Pharm; 2015 Feb; 41(2):315-21. PubMed ID: 24261406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preformulation studies for an ultrashort-acting neuromuscular blocking agent GW280430A. I. Buffer and cosolvent effects on the solution stability.
    Zhu H; Meserve K; Floyd A
    Drug Dev Ind Pharm; 2002; 28(2):135-42. PubMed ID: 11926357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of cefuroxime in 1% and 5% buffered eye drops determined with HPLC method.
    Kodym A; Wiśniewski A; Knioła D; Olejniczak M
    Acta Pol Pharm; 2011; 68(4):555-64. PubMed ID: 21796938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation development of frozen parenteral dosage forms.
    Chilamkurti RN
    J Parenter Sci Technol; 1992; 46(4):124-9. PubMed ID: 1453281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of formulation properties on chemical stability of captopril in aqueous preparations.
    Kristensen S; Lao YE; Brustugun J; Braenden JU
    Pharmazie; 2008 Dec; 63(12):872-7. PubMed ID: 19177902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist.
    Chang BS; Reeder G; Carpenter JF
    Pharm Res; 1996 Feb; 13(2):243-9. PubMed ID: 8932444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-1: the Effects of Metal Ions and Buffers.
    Jakaria SM; Budil DE; Murtagh J
    Pharm Res; 2023 Oct; 40(10):2469-2478. PubMed ID: 37697173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A critical evaluation of Tm(FTIR) measurements of high-concentration IgG1 antibody formulations as a formulation development tool.
    Matheus S; Mahler HC; Friess W
    Pharm Res; 2006 Jul; 23(7):1617-27. PubMed ID: 16783474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-buffering antibody formulations.
    Gokarn YR; Kras E; Nodgaard C; Dharmavaram V; Fesinmeyer RM; Hultgen H; Brych S; Remmele RL; Brems DN; Hershenson S
    J Pharm Sci; 2008 Aug; 97(8):3051-66. PubMed ID: 18023013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of phosphate buffer in parenteral drugs on particle formation from glass vials.
    Ogawa T; Miyajima M; Wakiyama N; Terada K
    Chem Pharm Bull (Tokyo); 2013; 61(5):539-45. PubMed ID: 23420583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of meropenem stability after reconstitution: the influence of buffering and challenges to meet the NHS Yellow Cover Document compliance for continuous infusions in an outpatient setting.
    Jamieson C; Allwood MC; Stonkute D; Wallace A; Wilkinson AS; Hills T;
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e53-e57. PubMed ID: 32296506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term stability of morphine hydrochloride in 0.9% NaCl infusion polyolefin bags after freeze-thaw treatment and in polypropylene syringes at 5 degrees C + 3 degrees C.
    Hecq JD; Godet M; Gillet P; Jamart J; Galanti L
    Int J Pharm Compd; 2014; 18(1):78-82. PubMed ID: 24881344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-formulation and chemical stability studies of penethamate, a benzylpenicillin ester prodrug, in aqueous vehicles.
    Jain R; Wu Z; Bork O; Tucker IG
    Drug Dev Ind Pharm; 2012 Jan; 38(1):55-63. PubMed ID: 21696334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of 'pH' on the Rate of Pyroglutamate Formation in Solution and Lyophilized Solids.
    Bersin LM; Patel SM; Topp EM
    Mol Pharm; 2021 Aug; 18(8):3116-3124. PubMed ID: 34232660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.